About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our research group is focused on studying the pathophysiology of migraine and other primary headaches using preclinical, translational and clinical research.
Migraine will allow us to define the brain’s adaptive, sensory/cognitive functions, through genetics, epigenetics, neurophysiology, neuromolecular and neuroanatomical information with an interest in developing clinical therapeutic solutions, with the goal on having an impact on suffering and increasing the well-being.
PMID: 34601944 Journal: CEPHALALGIA Year: 2022 Reference: Cephalalgia. 2022 Mar;42(3):186-196. doi: 10.1177/03331024211040467. Epub 2021 Oct 4. Impact factor: 6.295 Publication type: Paper in international publication Authors: Asskour, Laila, Caronna, Edoardo, Torres-Ferrus, Marta, Pozo-Rosich, Patricia, Gallardo, Victor J, Alpuente, Alicia et al. DOI: 10.1177/03331024211040467
PMID: 34282471 Journal: JOURNAL OF NEUROLOGY Year: 2022 Reference: J Neurol. 2022 Mar;269(3):1456-1462. doi: 10.1007/s00415-021-10715-2. Epub 2021 Jul 20. Impact factor: 4.849 Publication type: Paper in international publication Authors: Gallardo, Victor Jose, Alpuente, Alicia, Torres-Ferrus, Marta, Pozo-Rosich, Patricia, Caronna, Edoardo et al. DOI: 10.1007/s00415-021-10715-2
PMID: 33832802 Journal: NEUROLOGIA Year: 2021 Reference: Neurologia (Engl Ed). 2021 Mar 19;36(8):611-7. doi: 10.1016/j.nrl.2021.03.003. Impact factor: Publication type: Paper in international publication Authors: Alpuente, A; Caronna, E; Gago-Veiga, A B; Irimia Sieira, P; Jose Gallardo, V; Lopez-Bravo, A; Lopez-Veloso, A C; Porta-Etessam, J; Pozo-Rosich, P; Sanchez-Mateo, N M et al. DOI: 10.1016/j.nrl.2021.03.003
PMID: 34903177 Journal: JOURNAL OF HEADACHE AND PAIN Year: 2021 Reference: J Headache Pain. 2021 Dec 13;22(1):151. doi: 10.1186/s10194-021-01366-9. Impact factor: 7.277 Publication type: Paper in international publication Authors: Gallardo, Victor J, Alpuente, Alicia, Pozo-Rosich, Patricia, Torres-Ferrus, Marta, Caronna, Edoardo et al. DOI: 10.1186/s10194-021-01366-9
PMID: 34766205 Journal: Current Pain and Headache Reports Year: 2021 Reference: Curr Pain Headache Rep. 2021 Nov 11;25(11):73. doi: 10.1007/s11916-021-00987-8. Impact factor: 3.494 Publication type: Review in international publication Authors: Caronna, Edoardo, Pozo-Rosich, Patricia et al. DOI: 10.1007/s11916-021-00987-8
PMID: 34601726 Journal: HEADACHE Year: 2021 Reference: Headache. 2021 Oct;61(9):1403-1410. doi: 10.1111/head.14225. Epub 2021 Oct 3. Impact factor: 5.887 Publication type: Paper in international publication Authors: Gallardo, Victor J, Alpuente, Alicia, Cerda-Company, Xim, Torres-Ferrus, Marta, Sanchez Del Rio, Margarita, Lainez, Jose Miguel, Leira, Rogelio, Trochet, Jerome, Pozo-Rosich, Patricia et al. DOI: 10.1111/head.14225
Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.
